Main achievements
1. Identification of diagnostic/prognostic and drug response biomarkers are group contributions: oxidative stress and DNA methylation are complementary prognostic biomarkers in myelodysplastic syndromes (MDS) patients; plasmatic peroxides levels are good predictive biomarkers of response to erythropoiesis-stimulating agents in lower-risk MDS; drug transporters variants as good susceptibility and prognostic biomarkers in chronic myeloid leukemia (CML) and the hydropathy index of the HCDR3 sequences of chronic lymphocytic leukemia (CLL) cells allows the identification of a subgroup of CLL patients with intermediate prognostic features. Moreover, Blood-based specimens may be potential source of non-invasive DNA methylation cancer biomarkers in MDS.
2. The assessment of different immune cells’ status in neoplasias context revealed the impact of an immunosuppressive state on patients’ stratifications, prognosis, and therapy monitoring.
3. Evaluation of therapeutic potential of new compounds in different neoplasias to improve or overcome lack of response of current approaches
4. In the context of international networking, reviews in high-impact journals were published focused on therapy resistance, the impact of metabolism and hypoxia in cancer, the role of immune system in cancer prognosis and monitoring, the molecular mechanisms of tyrosine kinase inhibitors resistance in CML and the elaboration of international (European) guidelines/consensus on cancer (mainly dermatological) and skink allergic diseases.
Publications
Scientific interests and ongoing research projects
1. canSERV (Providing cutting edge cancer research services across Europe). IR: EATRIS. Particiapnts: Laranjeira P, Paiva A. Funding: European Comission HORIZON-INFRA-2021-SERV-01. 2021.
2. Clinical relevance of platelets as non-invasive biomarkers in diffuse large B-cell lymphoma – A pilot study. Coordinator: Sarmento Ribeiro AB. Participants: Gonçalves AC, Lapa B, Jorge J, Alves R, Geraldes C, Cortesão E, Carda JP. Funding: LPCC-NRC/CIMAGO, SPH 2021-2023.
CuidIn - Apoiar e Cuidar do Cuidador Informal (N/Ref.ª: 3695/POISE/EMPIS/SI/3.33/2020). Coordinators: Dourado M and Ferreira P. Funding: Portugal 2020/ POISE-03-4639-EU-FSE-000765. 2020-2023.
3. Eventos adversos imunológicos dos inibidores dos “check-point” imunológicos – estudo dos seus fenótipos e biomarcadores. Coordinator: Gonçalo M. Funding: FMUC- PEPITA. 2019-2022.
4. New diagnostic and therapeutic tools against multidrug resistant tumors - COST action CA17104. PI: Chiara Riganti (U Turin, Italy). Participant: Sarmento Ribeiro AB, Gonçalves AC, Alves R. Funding: European Comission-COST. 2018-2022.
5. Radiolabeled EXosomes - a nanotheranostic tool for lung micrometastasis in osteosarcoma. (PTDC/BTM-SAL/4451/2020). Coordinator: Gomes C. Funding: FCT. 2021-2023.
6. Red Transfronteriza de Innovación en Diagnóstico Precoz de Leucemia para un envejecimiento saludable – IDIAL-NET. Coordinators: Orfão A. and Sarmento Ribeiro AB. Funding: Interreg-POCTEP 2019-2022